Publication

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD), the most rapidly increasing and prevalent cause of chronic liver disease, is associated with substantial healthcare costs. As disease burden and costs mount, pharmacologic therapy which halts MASLD fibrosis progression is coming to fruition. Modeling the impact on disease progression of a hypothetical pharmacologic therapy which halts MASLD fibrosis progression through multiple scenarios provides insights into the key drivers of the disease and costs associated with it. This should help to facilitate best policies and practices to mitigate the burden of MASLD.